It is currently Sun Oct 04, 2015 8:41 am

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.


This is one of the drugs in the pipeline at Neuren. It is a neuro-protective drug and pre-clinical results look promising. I think it has just entered into Phase 1 human trials.

See 22 March news on the company's website.

Let's hope that the human trial results are as good

<shortened url>
Read more : NNZ-2566 | Views : 1372 | Replies : 0


Research article on Laquinimod. Good at reducing lesions but no impact on disability (isn't this what we want?)

<shortened url>
Read more : Laquinimod | Views : 1245 | Replies : 0

Oral Copaxone

Darn it... Just get me a pill! I hate these d*mn Rebif injections!!!!!!

<shortened url>
Read more : Oral Copaxone | Views : 1561 | Replies : 1


Rituximab (Rituxin) is currently being trialled for PP, SP, RR MS and targets the B cells.

Rituximab was recently approved (by the FDA) for use in severe Rheumatoid Arthritis. RA seems to have some similarities to MS in that there is differences in the levels of severity and different responses to treatments.

The following article is about Rituximab (renamed Mabthera) for RA.

Ian, ... 71,00.html
Read more : Rituximab | Views : 1988 | Replies : 4



A T cell vaccine (like Tovaxin) being trialled in Israel. Lokks like reults might be out in a few months.

Read more : Vaccine | Views : 1717 | Replies : 3

Sativex - not much use for spasticity

GW Pharma slumped today after the maker of cannabis medicines revealed some disappointing results from a recent Sativex study.
The company reported that results from Phase III studies into the cannabis-based medicine Sativex failed to reach statistical significance.

The trial was supposed to identify whether Sativex could be used to treat the relief of spasticity in people with Multiple Sclerosis.

"Analysis of the Intention to Treat population - incorporating all patients regardless of whether they ...
Read more : Sativex - not much use for spasticity | Views : 1281 | Replies : 0


FTY720 is seen by some as being the 'gold standard' for MS treatment in the future. Unfortunately, approval unlikely until 2010.

In recognition of my sterling efforts this week Arron has kindly offered me two free weeks at his villa in California. Many thanks Arron I'll keep the good work up.


Novartis: FTY720 offers gold standard MS potential 16 March 2006

Novartis drug to become preferred front-line agent for the treatment of multiple sclerosis. ...
Read more : FTY720 | Views : 2018 | Replies : 4

Overview of drugs

Nothing new but a summary of what's available / in the pipeline.
Read more : Overview of drugs | Views : 1456 | Replies : 0



Probably shouldn't go on the list as its only a possibility that it might be beneficial for MS.
Read more : exosomes | Views : 1270 | Replies : 1

MBP8298 For RRMS

BioMS Plans Relapsing-Remitting Multiple Sclerosis Trial

- MBP8298 to be tested in a second major MS patient population -

EDMONTON, Alberta, March 13, 2006 – BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it is expanding the clinical development program for its lead drug candidate MBP8298. The drug is currently undergoing an international pivotal phase II/III clinical trial with secondary progressive MS patients (SPMS). BioMS ...
Read more : MBP8298 For RRMS | Views : 1412 | Replies : 1


Login  •  Register


Total posts 227601 • Total topics 24030 • Total members 15391

Contact us | Terms of Service